SCHEMBL148108

SCHEMBL148108

NC(=O)c1cccc2c1[nH]c1cc(NC(=O)c3cncnc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.48
RPS6KB1 P23443 3/20 0.48
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
JAK2 O60674 4/20 0.42
SIRT2 Q8IXJ6 2/20 0.41
BTK Q06187 4/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
BRAF P15056 1/20 0.39
PKN1 Q16512 1/20 0.39
PKN2 Q16513 1/20 0.39
AURKB Q96GD4 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27998034 0.81 JAK2 (0.47) KDM4EMEN1CYP1A2CYP3A4CYP2C9
SCHEMBL146141 0.77 JAK2 (0.51) KDM4EJAK2BTKJAK1TYK2
SCHEMBL149424 0.77 ROCK2 (0.58) AURKARPS6KB1JAK2SIRT2AURKB
SCHEMBL149496 0.76 ROCK2 (0.58) AURKARPS6KB1CYP1A2CYP3A4CYP2C9
SCHEMBL149838 0.76 ROCK2 (0.47) KDM4EMEN1CYP1A2CYP3A4CYP2C9
SCHEMBL149891 0.76 PARP14 (0.56) AURKARPS6KB1JAK2AURKB
SCHEMBL148318 0.74 PIM1 (0.50) KDM4EMEN1KMT2AJAK2BTK
SCHEMBL150480 0.74 JAK2 (0.43) KDM4EMEN1CYP1A2CYP3A4CYP2C9
SCHEMBL27982043 0.73 BTK (0.62) AURKAJAK2BTKTYK2
SCHEMBL150223 0.73 CHUK (0.49) AURKARPS6KB1JAK2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 AURKA 248/4885RPS6KB1 293/4885KDM4E 733/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 AURKA 248/4885RPS6KB1 293/4885KDM4E 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.